COMBINATION THERAPY FOR TREATING CANCER

(19)

(11)

EP 4 140 487 A8

(12)	CORRECTED EUROPEAN PATENT APPLICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 A1)

(48)	Corrigendum issued on:
	06.09.2023 Bulletin 2023/36

(43)	Date of publication:
	01.03.2023 Bulletin 2023/09

(21)	Application number: 22177404.5

(22)	Date of filing: 12.04.2013

(51)

International Patent Classification (IPC):

A61K 31/5377^(2006.01)
A61P 35/00^(2006.01)
A61K 45/06^(2006.01)
A61K 31/704^(2006.01)
A61K 31/436^(2006.01)
A61K 31/53^(2006.01)
A61K 31/7068^(2006.01)
C07D 213/64^(2006.01)
A61P 25/00^(2006.01)

A61K 31/4412^(2006.01)
A61P 35/02^(2006.01)
A61K 31/573^(2006.01)
A61K 33/24^(2019.01)
A61K 31/4745^(2006.01)
A61K 31/675^(2006.01)
C07D 405/12^(2006.01)
A61K 33/243^(2019.01)
A61P 43/00^(2006.01)

(52)	Cooperative Patent Classification (CPC):
	A61K 31/4412; A61K 31/5377; A61K 45/06; A61K 31/436; A61K 31/53; A61K 31/573; A61K 31/704; A61K 31/7068; C07D 213/64; A61K 31/4745; A61K 31/675; C07D 405/12; A61K 33/243; A61K 33/24; A61P 25/00; A61P 35/00; A61P 35/02; A61P 43/00

	C-Sets:
	A61K 31/436, A61K 2300/00; A61K 31/53, A61K 2300/00; A61K 31/7068, A61K 2300/00; A61K 33/243, A61K 2300/00; A61K 31/4412, A61K 2300/00; A61K 31/573, A61K 2300/00; A61K 31/5377, A61K 2300/00; A61K 31/704, A61K 2300/00;

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

13.04.2012 US 201261624194 P
14.03.2013 US 201361785169 P

(62)	Application number of the earlier application in accordance with Art. 76 EPC:
	13776380.1 / 2836216

(71)	Applicant: Epizyme, Inc.
	Cambridge, MA 02139 (US)

(72)	Inventors:
	KEILHACK, Heike Belmont, 02478 (US) KNUTSON, Sarah, Kathleen Cambridge, 02138 (US) KUNTZ, Kevin, Wayne Woburn, 01801 (US)

(74)	Representative: Russell, Tim et al
	Venner Shipley LLP 200 Aldersgate London EC1A 4HD London EC1A 4HD (GB)


	Remarks:
	This application was filed on 06-06-2022 as a divisional application to the application mentioned under INID code 62.


	Remarks:
	Claims filed after the date of filing of the application (Rule 68(4) EPC).

(54)	COMBINATION THERAPY FOR TREATING CANCER

(57) The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, particularly anticancer agents such as prednisone, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.